Results 11 to 20 of about 9,493 (159)

Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post-Marketing Surveillance Sub-Analysis. [PDF]

EJHaem
ABSTRACT Background Thrombotic events (TEs) account for approximately 40%–67% of deaths in untreated paroxysmal nocturnal haemoglobinuria (PNH). C5 inhibitor treatment (e.g., eculizumab and ravulizumab) greatly reduces the incidence of TEs in patients with PNH, but data on the characteristics of PNH patients experiencing TEs are limited.
Ikezoe T, Kawaguchi T, Hayashi H, Shimono A, Nishimura JI.   +4 more
europepmc   +2 more sources

Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab". [PDF]

Ann Clin Transl Neurol
Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1303-1304, June 2026.
Gerischer L, Schroeder-Braunstein J, Wabnitz G, Meisel A.   +3 more
europepmc   +2 more sources

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study

Health Technology Assessment
Background Atypical haemolytic uraemic syndrome is a rare disease (incidence: 0.4 cases per million per year) which, without treatment, is associated with high morbidity and mortality.
Andrew Bryant, Jan Lecouturier, Giovany Orozco-Leal, Vicky Brocklebank, Sonya Carnell, Thomas J Chadwick, Sarah Dunn, Sally A Johnson, David Kavanagh, Ciara A Kennedy, Michal Malina, Emma K Montgomery, Colin R Muirhead, Yemi Oluboyede, Luke Vale, Chris Weetman, Edwin Kwan Soon Wong, Len Woodward, Neil S Sheerin   +18 more
doaj   +2 more sources

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2022
One of the treatment options for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome, is the administration of the C5 complement inhibitor eculizumab.
Meera Sridharan, MD, PhD, Ronald S. Go, MD, Maria A.V. Willrich, PhD   +2 more
doaj   +1 more source

Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome

Frontiers in Pediatrics, 2021
Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Saritha Ranabothu, Clare C. Brown, Richard Blaszak, Rachel Millner, Kristen Rice Moore, Parthak Prodhan   +5 more
doaj   +1 more source

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis

Frontiers in Neurology, 2021
Objective: To investigate the pharmacokinetics, pharmacodynamics, and exposure–response of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with generalized myasthenia gravis (gMG ...
Jonathan P. R. Monteleone, Xiang Gao, Huub Jan Kleijn, Francesco Bellanti, Ryan Pelto   +4 more
doaj   +1 more source

A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome

Children, 2022
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab.
Saeed AlZabali, Sawsan AlBatati, Khawla Rahim, Hassan Faqeehi, Abubaker Osman, Abdulaziz Bamhraz, Mohammed A. Saleh, Jameela A. Kari, Majed Aloufi, Loai Eid, Haydar Nasser, Abubakr Imam, Entesar AlHammadi, Omar Alkandari, Mohammed Al Riyami, Sidharth Sethi, Christoph Licht, Khalid A. Alhasan, Abdulkarim AlAnazi   +18 more
doaj   +1 more source

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report

Case Reports in Neurology, 2021
The recombinant humanized monoclonal antibody eculizumab has been shown to be effective and well tolerated in patients with anti-acetylcholine receptor antibody-positive, treatment-refractory generalized myasthenia gravis (gMG).
Tuan Vu, Brittany Harvey, Niraja Suresh, Jerrica Farias, Clifton Gooch   +4 more
doaj   +1 more source

Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series

Brain Sciences, 2021
(1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on
Marco Allinovi, Angelo Bellinvia, Francesco Pesce, Sabrina Milan Manani, Lorenzo Razzolini, Brigida Brezzi, Paolo Protopapa, Vittorio Mantero, Leonardo Caroti, Calogero Lino Cirami, Maria Pia Amato, Lucia Del Vecchio   +11 more
doaj   +1 more source

Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort

PLoS ONE, 2021
Background Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare disease that potentially leads to kidney graft failure due to ongoing Thrombotic Microangiopathy (TMA).
Hong Si Nga, Lilian Monteiro Pereira Palma, Miguel Ernandes Neto, Ida Maria Maximina Fernandes-Charpiot, Valter Duro Garcia, Roger Kist, Silvana Maria Carvalho Miranda, Pedro Augusto Macedo de Souza, Gerson Marques Pereira, Luis Gustavo Modelli de Andrade   +9 more
doaj   +2 more sources